“brighteningcare.com”的搜索结果，显示 821-830 项，共有 8978 项
The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of documentation of HLA-A LOH status; The percentage ...
Rochester, Minn. This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute ...
转诊医疗机构办公室是您的一站式团队，可为您的患者安排约诊，以及与妙佑医疗国际工作人员的电话咨询。
Rochester, Minn. The purpose of this study is to find out more about the side effects of the CAR-T therapy called IC19/1563 and what dose of IC19/1563 is safe ...
您的捐赠可以抵税。请您慷慨解囊，和我们一起进行尖端研究和医护，共同推动医学的改变。 慷慨捐赠.
Rochester, Minn. The purpose of this study is to evaluate the reduction in the peritoneal carcinomatosis index (PCI) after completion of the study treatment.
REVOLUTION will be a US multicenter observational registry in scope and governed by a steering committee of approximately 8 experts in NSCLC and outcomes ...
The aims of this study are to investigate the presence of tumor cells after filtration of autologous blood products by intraoperative cell saver, ...
Rochester, Minn., Jacksonville, Fla. This phase Ib trial studies the side effects and best dose of a vaccine called H2NVAC before surgery in treating patients ...
科室与专家门诊. 妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业，通过齐心 ...
妙佑医疗国际不为任何公司或产品背书。广告收入为我们的非营利使命提供支持。
浏览妙佑医疗国际出版社提供的畅销书以及书籍和简报的特别优惠。
您的捐赠可以抵税。请您慷慨解囊，和我们一起进行尖端研究和医护，共同推动医学的改变。